ABIGAIL KINKELLA: Open Payments
NPI 1982291241 · EVANS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$915 in 49 payments from 14 companies in 2025. Trend: 2023 $2,028 · 2024 $1,338 · 2025 $915
Food & beverage: $915
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $295 |
| ABBVIE INC. | 15 | $222 |
| PFIZER INC. | 4 | $91 |
| Abbott Laboratories | 3 | $52 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| Dexcom, Inc. | 2 | $41 |
| SHIELD THERAPEUTICS INC | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
Products named: Wegovy, Ozempic, UBRELVY, VRAYLAR, FREESTYLE LIBRE 3, ELIQUIS, Kerendia, Dexcom G6 Transmitter.
Industry payments across GA — which companies pay providers there.
